Synopsis
This meeting is of interest to industrial chemists to discover what their contemporaries are working on in other companies and other areas of research but also for academic chemists who want to find out the different challenges and focus that working in an industrial setting offers. It also presents a superb opportunity for younger chemists to showcase their industrial research to an external audience. Prizes will be awarded for the best talk and runners-up. In addition, a lecture from a leading industrial chemist will conclude the proceedings.
Attendees
This meeting is aimed at chemists working in the pharmaceutical, biotechnology or agrochemical sector and would provide them with a unique opportunity to discover what their contemporaries do in other branches of the industry. The meeting would also appeal to graduates and post-graduates with a background in organic chemistry.
Prizes
Prizes will be awarded for the best talk and runners-up. In addition, a lecture from a leading industrial chemist will conclude the proceedings.
Programme
10.00 Registration and refreshments
10.30 Introduction
10.35 Optimisation of a series of potent and selective GR antagonists
Benoit Gourdet, Sygnature Discovery
11.00 Fluorocompounds in cement - ‘bringing science to the sell’
Sheryl Johnson, Mexichem
11.25 Refreshment break
11.45 Synthetic approaches to a [1.1.1] bicyclopentane and its incorporation into darapladib as a phenyl bioisostere
Nicholas Measom, GlaxoSmithKline
12.10 The development of novel smoothened inhibitors with improved aqueous solubility and potential use as orally or topically administered anti-cancer agents
Louise Sargent, RedX Oncology
12.35 Lunch
13.30 Studies towards palladium sp3 C-H activation of tetraalkyl piperazine-based scaffolds
Thomas Alanine, AstraZeneca
13.55 Tentoxin: exploring small cyclic peptides as herbicides
Elizabeth Frye, Syngenta
14.20 Osimertinib mesylate: process development and scale-up of an API on the critical path
Shaun Hughes, AstraZeneca
14.45 Refreshment break
15.10 N-Functionalisation of tertiary amines powered by visible light
Joshua Barham, GlaxSmithKline
15.35 Plenary talk: discovery and characterisation of potent and selective inhibitors of ATR kinase as anti-cancer agents
Joanne Pinder, Vertex
16.20 Prize giving followed by wine reception
Organising Committee
Kiri Stevens, SCI/Vertex, UK
Ian Strutt, SCI/Sygnature Discovery, UK
Gail Wrigley, SCI/AstraZeneca , UK
Rob Wybrow, SCI/Syngenta, UK
Delegate Fees
This event is free to attend.
Venue
Vertex Pharmaceuticals (Europe) Ltd
86-88 Jubilee Avenue
Milton Park
Abingdon
Oxfordshire
OX14 4RW
UK
This meeting is of interest to industrial chemists to discover what their contemporaries are working on in other companies and other areas of research but also for academic chemists who want to find out the different challenges and focus that working in an industrial setting offers. It also presents a superb opportunity for younger chemists to showcase their industrial research to an external audience. Prizes will be awarded for the best talk and runners-up. In addition, a lecture from a leading industrial chemist will conclude the proceedings.
Attendees
This meeting is aimed at chemists working in the pharmaceutical, biotechnology or agrochemical sector and would provide them with a unique opportunity to discover what their contemporaries do in other branches of the industry. The meeting would also appeal to graduates and post-graduates with a background in organic chemistry.
Prizes
Prizes will be awarded for the best talk and runners-up. In addition, a lecture from a leading industrial chemist will conclude the proceedings.
Programme
10.00 Registration and refreshments
10.30 Introduction
10.35 Optimisation of a series of potent and selective GR antagonists
Benoit Gourdet, Sygnature Discovery
11.00 Fluorocompounds in cement - ‘bringing science to the sell’
Sheryl Johnson, Mexichem
11.25 Refreshment break
11.45 Synthetic approaches to a [1.1.1] bicyclopentane and its incorporation into darapladib as a phenyl bioisostere
Nicholas Measom, GlaxoSmithKline
12.10 The development of novel smoothened inhibitors with improved aqueous solubility and potential use as orally or topically administered anti-cancer agents
Louise Sargent, RedX Oncology
12.35 Lunch
13.30 Studies towards palladium sp3 C-H activation of tetraalkyl piperazine-based scaffolds
Thomas Alanine, AstraZeneca
13.55 Tentoxin: exploring small cyclic peptides as herbicides
Elizabeth Frye, Syngenta
14.20 Osimertinib mesylate: process development and scale-up of an API on the critical path
Shaun Hughes, AstraZeneca
14.45 Refreshment break
15.10 N-Functionalisation of tertiary amines powered by visible light
Joshua Barham, GlaxSmithKline
15.35 Plenary talk: discovery and characterisation of potent and selective inhibitors of ATR kinase as anti-cancer agents
Joanne Pinder, Vertex
16.20 Prize giving followed by wine reception
Organising Committee
Kiri Stevens, SCI/Vertex, UK
Ian Strutt, SCI/Sygnature Discovery, UK
Gail Wrigley, SCI/AstraZeneca , UK
Rob Wybrow, SCI/Syngenta, UK
Delegate Fees
This event is free to attend.
Venue
Vertex Pharmaceuticals (Europe) Ltd
86-88 Jubilee Avenue
Milton Park
Abingdon
Oxfordshire
OX14 4RW
UK
